GlaxoSmithKline (“GSK”), maker of anti-nausea drug Zofran (ondansetron), has filed a request with the U.S. Judicial Panel on Multidistrict Litigation asking it to consolidate a dozen lawsuits pending against GSK in ten judicial districts across the country—including three suits filed by Grant & Eisenhofer, the first law firm to file a Zofran (ondansetron) birth defect case. The lawsuits all allege that Zofran (ondansdetron) caused severe birth defects in children whose mothers took the drug for morning sickness during the first trimester of pregnancy. The request, reported by Reuters to have been entered in early July 2015, seeks to consolidate these cases to a Pennsylvania court as a multidistrict litigation, or MDL, which combines and centralizes lawsuits with similar claims for expedited discovery and other pretrial proceedings. The cases allege that GSK promoted Zofran (ondansetron) “off label,” or for uses not approved by the FDA, to doctors prescribing the drug to patients experiencing nausea and vomiting associated with pregnancy, causing fetal heart malformations and cleft palate, among other defects.